3Jules L, Disnstag J C, Sclim K, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology, 2003,37 (4) : 749-755
4Liaw YF, Leung NWY, Chang TF, et al.Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Gastroenterology, 2000,119 : 172 - 180
5Chang TT, Lai CL, l,iaw YF, et al. Incremenlal increascs in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years( abstr). Antiviral Therapy, 2000,5( Suppl 1 ) : 44
6Song BC, Sub DJ, Lee HC, et al. Hepatitis B e antigen seroeonversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology, 2000,32 : 803 - 806
7Honkoop P,de Man RA, Niesters HGN, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology, 2000,32 : 635 - 639
8Kobayashi S, Ide T, Sata M, et al. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol ,2001,34:584 - 586
9Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during larnivudine treatment. J Hepatol, 2002,37 : 259 ~ 265
10Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase duringa lamivudine therapy. J gastroenterol hepatol, 2003,1353 : 1357
